{"id":"W4389246942","doi":"10.1182/blood-2023-182119","title":"Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); Chemotherapy regimen; Neutropenia; Chemotherapy; Phases of clinical research; Immunotherapy; Cancer; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003121018,0.002176054,0.003235028,0.000587501,0.0006767177,0.001580425,0.001441471,0.002458024,0.008074566],"category_scores_gemma":[0.002496628,0.0009268907,0.001832953,0.0005830551,0.002353075,0.001873918,0.0006423116,0.004655324,0.001605735],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001772214,"about_ca_system_score_gemma":0.002181632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001397132,"about_ca_topic_score_gemma":0.002912418,"domain_scores_codex":[0.9989092,0.0005685078,0.00004577597,0.0001907842,0.00008059611,0.00020513],"domain_scores_gemma":[0.9977525,0.0004978818,0.0004348823,0.0002089462,0.0001503666,0.000955538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9688803,0.01941927,0.0005990731,0.0001748908,0.0003787783,0.00003212939,0.00004726558,0.0002892329,0.002231364,0.00006855662,0.0005354125,0.007343803],"study_design_scores_gemma":[0.8771739,0.1202409,0.001213489,0.000009968021,0.0001461309,0.00002781686,0.00002007364,0.0003320846,0.0002884022,0.000110241,0.0004264778,0.00001057666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830155,0.00164485,0.0008405566,0.0006311631,0.000548183,0.009517571,0.001443726,0.0001944541,0.002164087],"genre_scores_gemma":[0.9778739,0.001098407,0.002859888,0.001651464,0.0006379061,0.01057845,0.001800233,0.0000497147,0.003450131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008074566,"threshold_uncertainty_score":0.02701205,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03583989734029489,"score_gpt":0.3232739564072745,"score_spread":0.2874340590669796,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}